The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review

Published:2022-05 Issue:5 Volume:3 Page:100315
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Mansfield Aaron S.,Brown Rebecca J.,Sammon Cormac,Daumont Melinda J.,McKenna Mike,Sanzari Jenine K.,Forde Patrick M.

Funder

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Baas;Ann Oncol,2015

2. Epidemiology of mesothelioma;Cavone;Environments,2019

3. Temporal and spatial heterogeneity of programmed cell death 1-ligand 1 expression in malignant mesothelioma;Terra;OncoImmunology,2017

4. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database;Van Gerwen;Carcinogenesis,2019

5. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM);Cedrés;PLoS One,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non‐small cell lung cancer;International Journal of Cancer;2024-06-20

2. Epithelioid pleural mesothelioma successfully treated with perioperative immunotherapy: a case report;General Thoracic and Cardiovascular Surgery Cases;2024-06-11

3. Contemporary management of mesothelioma;Breathe;2024-06

4. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy;Cancers;2023-12-10

5. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial;The Lancet;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3